読み込み中
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
終値時点
$2.42
+$0.01 · +0.41%
時間外
$2.42
$0.00 · 0.00%
10月12日 16:10 ET
日中の時刻はETです。市場データは遅延する場合があります。
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
日中レンジ
現在 $2.42
52週レンジ
現在 $2.42
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
47
適正価値
センチメント
50
まちまち
リスク
41
やや高いリスク
モメンタム
61
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
日中レンジ
現在 $2.42
52週レンジ
現在 $2.42
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 83万 USD | — | — | — | 5万 USD |
| 粗利益 | −83万 USD | — | — | — | −5万 USD |
| 研究開発 | 4826万 USD | 4379.5万 USD | 3211.5万 USD | 2586.2万 USD | 2811.9万 USD |
| 販売・一般管理 | 1469万 USD | 1059.1万 USD | 481.9万 USD | 390.4万 USD | 1164.9万 USD |
| 営業費用 | 6212万 USD | 5438.6万 USD | 3693.4万 USD | 2976.6万 USD | 3976.8万 USD |
| 受取利息 | 344.1万 USD | 201.3万 USD | 162.3万 USD | 25.4万 USD | — |
| 支払利息 | — | 30万 USD | — | — | — |
| 減価償却費と償却費 | 83万 USD | 66.2万 USD | 56万 USD | 38.7万 USD | 5万 USD |
| 営業利益 | −6295万 USD | −5438.6万 USD | −3693.4万 USD | −2976.6万 USD | −3981.8万 USD |
| 純利益 | −5951.7万 USD | −5267.3万 USD | −3531.1万 USD | −2951.2万 USD | −3977万 USD |
会社概要が更新されました 2026年10月12日.
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI418.93万0.00%2.3兆 USD0.03%$381.57-0.10%
iShares Russell 2000 ETFIWM139.01万0.00%787.4億 USD0.19%$277.9-0.37%
Vanguard Extended Market ETFVXF110.98万0.00%954億 USD0.05%$233.52-0.63%
Vanguard Russell 2000 ETFVTWO54.77万0.00%180億 USD0.06%$112.27-0.35%
T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMED22.46万0.68%3296.48万 USD0.44%$33.6345-0.70%
iShares Micro-Cap ETFIWC19.99万0.02%13.17億 USD0.60%$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM13万0.11%1.17億 USD0.73%$15.8484-0.58%
Vanguard Russell 2000 Value ETFVTWV8.81万0.01%14億 USD0.06%$185.97+0.08%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMEDiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMVanguard Russell 2000 Value ETFVTWVAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
